Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

2.73
-0.1900-6.51%
Post-market: 2.730.00000.00%19:40 EDT
Volume:1.47M
Turnover:4.01M
Market Cap:311.22M
PE:-2.05
High:2.89
Open:2.88
Low:2.66
Close:2.92
52wk High:6.16
52wk Low:1.96
Shares:114.00M
Float Shares:68.28M
Volume Ratio:0.90
T/O Rate:2.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3300
EPS(LYR):-1.3971
ROE:-39.57%
ROA:-22.28%
PB:0.96
PE(LYR):-1.95

Loading ...

Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer

TIPRANKS
·
Jun 01

H.C. Wainwright Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
Jun 01

Perspective Therapeutics shareholders elect six directors at annual meeting

Reuters
·
May 28

Perspective Therapeutics reports 29% response rate in [212Pb]VMT01 melanoma cohort 3.0 mCi trial

Reuters
·
May 22

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

GlobeNewswire
·
May 22

Perspective Therapeutics doses first patients in two Phase 1/2a studies

TIPRANKS
·
May 18

Perspective Therapeutics doses first patient in new VMT-α-NET Phase 1/2a cohort

Reuters
·
May 18

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

THOMSON REUTERS
·
May 18

LifeSci Capital Remains a Buy on Perspective Therapeutics (CATX)

TIPRANKS
·
May 16

Perspective Therapeutics price target lowered to $6 from $7 at BofA

TIPRANKS
·
May 13

Analysts Are Bullish on These Healthcare Stocks: SI-Bone (SIBN), Perspective Therapeutics (CATX)

TIPRANKS
·
May 12

Piper Sandler Remains a Buy on Perspective Therapeutics (CATX)

TIPRANKS
·
May 12

BTIG Remains a Buy on Perspective Therapeutics (CATX)

TIPRANKS
·
May 12

RBC Capital Sticks to Its Buy Rating for Perspective Therapeutics (CATX)

TIPRANKS
·
May 12

Perspective Therapeutics reports Q1 EPS (25c), consensus (30c)

TIPRANKS
·
May 12

Perspective Therapeutics Highlights Q1 Progress and Strengthened Finances

TIPRANKS
·
May 12

Perspective Therapeutics Q1 net loss widens as grant revenue drops

Reuters
·
May 12

Perspective Therapeutics Q1 EPS $(0.25) Beats $(0.31) Estimate, Sales $76.000K Miss $136.917K Estimate

Benzinga Earnings
·
May 12

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

THOMSON REUTERS
·
May 12

Perspective Therapeutics Q1 EPS USD -0.25

THOMSON REUTERS
·
May 12